The European Pharmacopoeia Commission (EPC) elected its new Chair, Dr Eugenia Cogliandro, at its 181st Session held on 25 and 26 March 2025. She will take up her duties at the 182nd Session of the EPC on 17 June 2025 for a three-year term.
Dr Cogliandro has been a member of the Italian delegation to the EPC since 2009 and was elected first Vice-Chair of the EPC for the 2022-2025 term.
For the past 26 years, she has worked at the Italian national competent authority for human medicinal products (originally the Ministry of Health and then the Italian Medicines Agency-AIFA) in several positions, all related to the quality of medicines. As of 2010, she has co-ordinated activities related to the quality assessment of chemical products in both national and European authorisation procedures, as well as to other quality-related issues for those aspects impacting registration dossiers, such as GMP issues, and outcomes of OMCL annual control programmes. Prior to this, she worked in the research field, first in an academic setting and then at the National Research Council, where she developed her expertise in analytical chemistry and participated in a large number of studies published in prestigious international journals. Her scientific expertise is combined with an in-depth knowledge of the regulatory framework, gained through her participation in several international working groups of both the European Commission and European Medicines Agency.
The European Directorate for the Quality of Medicines & HealthCare (EDQM) and the European Pharmacopoeia family congratulate Dr Cogliandro on her election and look forward to many more years of close and productive collaboration.
For more information on the decisions taken by the EPC at its 181st session, read the news item “Outcome of the 181st session of the European Pharmacopoeia Commission, March 2025”.
See also: